SCHEMBL1994923

SCHEMBL1994923

Cn1c(C(=O)N2CCC(NCc3cccc(F)c3)(C(N)=O)CC2)cc(-c2ccccc2Cl)c1-c1ccc(OCC(N)=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 6/20 0.40
ALDH1A1 P00352 3/20 0.35
TSHR P16473 1/20 0.35
NTRK1 P04629 2/20 0.35
CNR2 P34972 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
TACR1 P25103 1/20 0.34
KMT2A Q03164 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
ADAMTS7 Q9UKP4 1/20 0.34
ADAMTS5 Q9UNA0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1128022 0.93 CNR1 (0.40) CNR1ALDH1A1TSHRNTRK1CNR2
SCHEMBL1985030 0.93 CNR1 (0.41) CNR1CNR2ADAMTS7ADAMTS5
SCHEMBL1987361 0.92 CNR1 (0.40) CNR1CNR2MAOAMAOBADAMTS7
SCHEMBL1990962 0.86 CNR1 (0.42) CNR1ALDH1A1TSHRCNR2
SCHEMBL1987339 0.86 CNR1 (0.41) CNR1CNR2ADAMTS7ADAMTS5
SCHEMBL1990958 0.85 CNR1 (0.46) CNR1CNR2
SCHEMBL1127431 0.85 CNR1 (0.42) CNR1ALDH1A1TSHRCNR2
SCHEMBL1127694 0.85 CNR1 (0.40) CNR1CNR2ADAMTS7ADAMTS5
SCHEMBL1985069 0.84 CNR1 (0.42) CNR1CNR2
SCHEMBL12601847 0.81 CNR1 (0.37) CNR1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383666-B2 Pyrrole derivatives, preparation of same and therapeutic application thereof SANOFI (FR) 2013-02-26 US disclosed
US-8383666-B2 Pyrrole derivatives, preparation of same and therapeutic application thereof SANOFI (FR) 2013-02-26 US disclosed
EP-2283008-B1 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2011-11-02 EP disclosed
US-20110144157-A1 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-06-16 US disclosed
US-20110144157-A1 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-06-16 US disclosed
WO-2009141533-A2 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144157-A1 PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF ARG2, PYCR1, ARG1 CNR1 548/4885ALDH1A1 900/4885TSHR 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.